E. van Brummelen
Netherlands Cancer Institute
11 Papers
51 Citations
E. van Brummelen is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 6, co-authored 11 publications.
Chat about Author
Papers
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
Patrick A. Ott,Sarina Anne Piha-Paul,Pamela N. Munster,Michael J. Pishvaian,E. van Brummelen,Roger B. Cohen,Carlos Gomez-Roca,Samuel Ejadi,Mark N. Stein,Emily Chan,Matteo Simonelli,Anne Morosky,Sanatan Saraf,Kenneth Emancipator,Minori Koshiji,Jaafar Bennouna +15 more
TL;DR: In this population of patients with PD-L1-positive advanced squamous cell anal carcinoma, pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity.
232
315O_PRAntitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study
C.-H. Hsu,Sang Hyub Lee,Samuel Ejadi,Caroline Even,Roger B. Cohen,C. Le Tourneau,Janice M. Mehnert,Alain Algazi,E. van Brummelen,Sanatan Saraf,Pradeep Thanigaimani,Jonathan D. Cheng,Aaron R. Hansen +12 more
29
500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
Patrick A. Ott,Sarina Anne Piha-Paul,Pamela N. Munster,Michael J. Pishvaian,E. van Brummelen,Roger B. Cohen,Carlos Gomez-Roca,Samuel Ejadi,Mark N. Stein,Emily Chan,Matteo Simonelli,Anne Morosky,S.S. Yuan,Minori Koshiji,Jaafar Bennouna +14 more
17
1181PPharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25
E. van Brummelen,Ulrik Lassen,I. Melero,J. Tabernero,Krisztian Homicsko,Eric Angevin,Volker Teichgräber,L. Jukofsky,E. Rossmann,G. Babitzki,A. Patricia Silva,Marta Cañamero,Christophe Boetsch,Stefan Evers,Jehad Charo,Guillem Argiles +15 more
7
84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)
Patrick A. Ott,Y-J. Bang,Albiruni Ryan Abdul Razak,Jaafar Bennouna,J-C. Soria,Hope S. Rugo,Roger B. Cohen,Bert H. O'Neil,Janice M. Mehnert,Juanita Lopez,Toshihiko Doi,E. van Brummelen,Diane Levitan,G. Zhao,Kenneth Emancipator,Karen Stein,Andrew K. Joe,M. Ayers,Jared Lunceford,Sarina Anne Piha-Paul +19 more
6